2 weeks Ago By Defense World Staff
Corebridge Financial Inc. reduced its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 7.
0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,098 shares of the biopharmaceutical company’s stock after selling 2,122 shares during the period. Corebridge Financial Inc.
’s holdings in Agios Pharmaceuticals were worth $923,000 at the end of the most recent reporting period. Other institutional investors and hedge funds have also bought and sold shares of the company. KBC Group NV raised its position in shares of Agios Pharmaceuticals by 30.
5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Agios Pharmaceuticals by 6.
0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 688 shares during the period. Atria Investments Inc raised its holdings in Agios Pharmaceuticals by 6.
9% in the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company’s stock worth $373,000 after purchasing an additional 737 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at $33,000.
Finally, Swiss National Bank lifted its position in Agios Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 100,760 shares of the biopharmaceutical company’s stock valued at $3,311,000 after buying an additional 1,000 shares during the period.
Insider ActivityIn other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.
72. Following the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08.
The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Insiders own 4.93% of the company’s stock. Agios Pharmaceuticals Trading Down 7.
0 %AGIO stock opened at $25.76 on Friday. The stock’s 50 day simple moving average is $32.
55 and its 200 day simple moving average is $40.23. Agios Pharmaceuticals, Inc.
has a 12-month low of $25.26 and a 12-month high of $62.58.
The stock has a market capitalization of $1.48 billion, a PE ratio of 2.27 and a beta of 0.
90. Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.
74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05).
Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.
On average, research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.
Analyst Ratings ChangesSeveral research analysts recently issued reports on the stock. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.
00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th.
Royal Bank of Canada lifted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th.
HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock.
Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $56.
57.Check Out Our Latest Research Report on Agios PharmaceuticalsAbout Agios Pharmaceuticals (Free Report)Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured ArticlesFive stocks we like better than Agios PharmaceuticalsStocks with Unusual Volume: How to Find Unusual Volume Stocks in Real TimeConagra Stock Could Thrive as Tariffs Hit Other SectorsWhat is the MACD Indicator and How to Use it in Your TradingGrocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey FindsBest of the list of Dividend Aristocrats: Build wealth with the aristocrat indexSpotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?.
